Veracyte, Inc. (FRA:12V)

Market Cap	2.86B +43.6%
Revenue (ttm)	491.83M +17.3%
Net Income	100.21M +334.7%
EPS	1.22 +315.4%
Shares Out	n/a
PE Ratio	28.51
Forward PE	22.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	35.59
Previous Close	35.25
Day's Range	35.59 - 35.59
52-Week Range	24.40 - 52.72
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About Veracyte

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its n...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2006
• Employees: 755
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 12V

Financial Performance

In 2025, Veracyte's revenue was $517.15 million, an increase of 16.01% compared to the previous year's $445.76 million. Earnings were $66.35 million, an increase of 174.89%.

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 25, 2026

Data Sources Report a data error